Table 3. Comparison of selected clinical and imaging variables in COVID-19 patients with and without myocarditis scar on follow-up.
| Variable | N | Scar + (n = 27) | Scar–(n = 66) | P-value |
|---|---|---|---|---|
| Clinical variables | ||||
| Female | 93 | 13 (48%) | 36 (55%) | 0.58 |
| Age | 93 | 58 ± 8 | 60 ± 11 | 0.19 |
| Length of hospitalization (days) | 93 | 11 (8–16) | 5 (8–22) | 0.17 |
| COVID-19 vaccination | 80 | 5 (20%) | 11 (20%) | 1.00 |
| ICU treatment | 93 | 14 (47%) | 40 (67%) | 0.44 |
| Laboratory variables at baseline | ||||
| Troponin elevation | 72 | 5 (22%) | 10 (20%) | 0.69 |
| C-reactive protein (mg/l) | 93 | 184 (108–246) | 158 (108–235) | 0.69 |
| Laboratory variables at follow-up | ||||
| Hs-TnI (ng/l) | 93 | 3 (3–5) | 3 (3–5) | 0.99 |
| NT-ProBNP (ng/l) | 93 | 53 (35–98) | 73 (35–119) | 0.48 |
| Glomerular filtration rate (ml/min) | 93 | 90 (83–99) | 91 (81–98) | 0.85 |
| Cardiac magnetic resonance imaging | ||||
| LVEDV (ml/m2) | 93 | 77 (68–89) | 76 (68–85) | 0.40 |
| LVEF (%) | 93 | 57 (55–61) | 61 (57–64) | 0.01 |
| LV mass (g/m2) | 93 | 53 ± 10 | 51 ± 11 | 0.33 |
| RVEDV (ml/m2) | 93 | 80 ± 15 | 79 ± 14 | 0.62 |
| RVEF (%) | 93 | 59 (55–62) | 58 (55–62) | 0.55 |
Data are presented as number of patients (%) or mean ± SD, or median (interquartile range). COVID-19 = coronavirus disease 2019; Hs-TnI = high-sensitivity troponin-I; LGE = late gadolinium enhancement; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; NT-ProBNP = N-terminal pro B-type natriuretic peptide; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction.